share_log

百利天恒(688506.SH):注射用 BL-M08D1(ADC)项目治疗复发或难治性血液系统恶性肿瘤和局部晚期或转移性实体瘤获得药物临床试验批准通知书

Baili Tianheng (688506.SH): The drug clinical trial approval notice for the injectable BL-M08D1 (ADC) project has been obtained for the treatment of relapsed or refractory hematologic malignancies and locally advanced or metastatic solid tumors.

Gelonghui Finance ·  Nov 28, 2024 10:05

On November 28, Gelonghui reported that Bailitianheng (688506.SH) announced that the company recently received the "Drug Clinical Trial Approval Notice" officially issued by the National Medical Products Administration (NMPA), and the clinical trial for the innovative biopharmaceutical BL-M08D1 (ADC) developed independently by the company has been approved.

BL-M08D1 is an ADC drug that originates from the same small molecule technology platform as BL-B01D1 and shares the same "linker + toxin" platform with BL-B01D1, indicated for recurrent or refractory hematologic malignancies and locally advanced or metastatic solid tumors.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
Comment Comment · Views 269

Recommended

Write a comment

Statement

This page is machine-translated. Moomoo tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation.